Related references
Note: Only part of the references are listed.Algenpantucel-L immunotherapy in pancreatic adenocarcinoma
Andrew L. Coveler et al.
IMMUNOTHERAPY (2016)
Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial
Johan F. Vansteenkiste et al.
LANCET ONCOLOGY (2016)
Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2
Ada Yeste et al.
SCIENCE SIGNALING (2016)
Coronary vasculature patterning requires a novel endothelial ErbB2 holoreceptor
Haig Aghajanian et al.
NATURE COMMUNICATIONS (2016)
Tolerogenic nanoparticles inhibit T cell-mediated autoimmunity through SOCS2
Ada Yeste et al.
SCIENCE SIGNALING (2016)
Humoral Immune Response against Nontargeted Tumor Antigens after Treatment with Sipuleucel-T and Its Association with Improved Clinical Outcome
Debraj GuhaThakurta et al.
CLINICAL CANCER RESEARCH (2015)
Rheumatoid arthritis vaccine therapies: perspectives and lessons from therapeutic ligand epitope antigen presentation system vaccines for models of rheumatoid arthritis
Kenneth S. Rosenthal et al.
EXPERT REVIEW OF VACCINES (2015)
Therapeutic cancer vaccines
Cornelis J. M. Melief et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Safety and Survival With GVAX Pancreas Prime and Listeria Monocytogenes-Expressing Mesothelin (CRS-207) Boost Vaccines for Metastatic Pancreatic Cancer
Dung T. Le et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
HCV epitope, homologous to multiple human protein sequences, induces a regulatory T cell response in infected patients
Phyllis T. Losikoff et al.
JOURNAL OF HEPATOLOGY (2015)
Immune Tolerance Induction with Multiepitope Peptide Derived from Citrullinated Autoantigens Attenuates Arthritis Manifestations in Adjuvant Arthritis Rats
Smadar Gertel et al.
JOURNAL OF IMMUNOLOGY (2015)
Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial
Cornelia L. Trimble et al.
LANCET (2015)
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III study
James Schuster et al.
NEURO-ONCOLOGY (2015)
Citrullinated peptide dendritic cell immunotherapy in HLA risk genotype-positive rheumatoid arthritis patients
Helen Benham et al.
SCIENCE TRANSLATIONAL MEDICINE (2015)
Oncogenic cancer/testis antigens: prime candidates for immunotherapy
Morten F. Gjerstorff et al.
ONCOTARGET (2015)
H7N9 T-cell epitopes that mimic human sequences are less immunogenic and may induce Treg-mediated tolerance
Rui Liu et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2015)
Preclinical development and first-in-human study of ATX-MS-1467 for immunotherapy of MS
Heather B. Streeter et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2015)
Elimination of IL-10-Inducing T-Helper Epitopes from an IGFBP-2 Vaccine Ensures Potent Antitumor Activity
Denise L. Cecil et al.
CANCER RESEARCH (2014)
Is the 3+3 Dose-Escalation Phase I Clinical Trial Design Suitable for Therapeutic Cancer Vaccine Development? A Recommendation for Alternative Design
Osama E. Rahma et al.
CLINICAL CANCER RESEARCH (2014)
The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response
Erika J. Schneble et al.
IMMUNOTHERAPY (2014)
From classic to spontaneous and humanized models of multiple sclerosis: Impact on understanding pathogenesis and drug development
Avraham Ben-Nun et al.
JOURNAL OF AUTOIMMUNITY (2014)
DNA vaccine for cancer immunotherapy
Benjamin Yang et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Tecemotide: An antigen-specific cancer immunotherapy
Gregory T. Wurz et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
Immune camouflage: Relevance to vaccines and human immunology
Anne S. De Groot et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2014)
EAE is not a useful model for demyelinating disease
Peter O. Behan et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2014)
TH2 Cytokines from Malignant Cells Suppress TH1 Responses and Enforce a Global TH2 Bias in Leukemic Cutaneous T-cell Lymphoma
Emmanuella Guenova et al.
CLINICAL CANCER RESEARCH (2013)
Different amounts of protein-bound citrulline and homocitrulline in foot joint tissues of a patient with anti-citrullinated protein antibody positive erosive rheumatoid arthritis
Sanna Turunen et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Therapeutic Antibodies Against Cancer
Mark J. Adler et al.
HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA (2012)
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Erika Hamilton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
A Cancer Vaccine Induces Expansion of NY-ESO-1-Specific Regulatory T Cells in Patients with Advanced Melanoma
Lisa M. Ebert et al.
PLOS ONE (2012)
The immune contexture in human tumours: impact on clinical outcome
Wolf Herman Fridman et al.
NATURE REVIEWS CANCER (2012)
Immunologic biomarkers as correlates of clinical response to cancer immunotherapy
Mary L. Disis
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Antigen Spreading Contributes to MAGE Vaccination-Induced Regression of Melanoma Metastases
Veronique Corbiere et al.
CANCER RESEARCH (2011)
NY-ESO-1 DNA Vaccine Induces T-Cell Responses That Are Suppressed by Regulatory T Cells
Sacha Gnjatic et al.
CLINICAL CANCER RESEARCH (2009)
Concurrent Trastuzumab and HER2/neu-Specific Vaccination in Patients With Metastatic Breast Cancer
Mary L. Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Negative feedback control of the autoimmune response through antigen-induced differentiation of IL-10-secreting Th1 cells
Leona Gabrysova et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
The cancer vaccine roller coaster
Bruce Goldman et al.
NATURE BIOTECHNOLOGY (2009)
Phase 2 trial of a DNA vaccine encoding myelin basic protein for multiple sclerosis
Hideki Garren et al.
ANNALS OF NEUROLOGY (2008)
Induction of immune response against NY-ESO-1 by CHP-NY-ESO-1 vaccination and immune regulation in a melanoma patient
Kazuhide Tsuji et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2008)
Insulin-like Growth Factor-Binding Protein-2 Is a Target for the Immunomodulation of Breast Cancer
Kyong Hwa Park et al.
CANCER RESEARCH (2008)
Induction of antigen-specific tolerance in multiple sclerosis after immunization with DNA encoding myelin basic protein in a randomized, placebo-controlled phase 1/2 trial
Amit Bar-Or et al.
ARCHIVES OF NEUROLOGY (2007)
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer
Eric J. Small et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel
VA Lennon et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2005)
One NY-ESO-1-derived epitope that promiscuously binds to multiple HLA-DR and HLA-DP4 molecules and stimulates autologous CD4+ T cells from patients with NY-ESO-1-expressing melanoma
M Mandic et al.
JOURNAL OF IMMUNOLOGY (2005)
Specific autoantibodies precede the symptoms of rheumatoid arthritis - A study of serial measurements in blood donors
MMJ Nielen et al.
ARTHRITIS AND RHEUMATISM (2004)
Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma
NG Chakraborty et al.
HUMAN IMMUNOLOGY (2004)
Determinant spreading and tumor responses after peptide-based cancer immunotherapy
A Ribas et al.
TRENDS IN IMMUNOLOGY (2003)
Anticitrullinated protein/pepticle antibody assays in early rheumatoid arthritis for predicting five year radiographic damage
O Meyer et al.
ANNALS OF THE RHEUMATIC DISEASES (2003)
Generation of T-cell immunity to the HER-2/neu protein after active immunization with HER-2/neu peptide-based vaccines
ML Disis et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Influence of a dominant cryptic epitope on autoimmune T cell tolerance
SM Anderton et al.
NATURE IMMUNOLOGY (2002)